{
  "docId": "019de071-eb84-776b-8e7d-ce40a476afec",
  "docSlug": "ee62a94395a2a2b10c5eb93465b3bf02",
  "documentTitle": "Kymera | Investor Day Presentation Deck | 105 slides",
  "authorId": "kymera",
  "authorName": "Kymera",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 55,
  "pageCount": 105,
  "prevPage": 54,
  "nextPage": 56,
  "slideType": "other",
  "function": "present_framework",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The diagram illustrates a multi-arm clinical trial design with dose escalation (DL1, DL2, DLx) leading to MTD/RP2D expansion cohorts for various indications, including combination therapy arms.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de071-eb84-776b-8e7d-ce40a476afec/55",
  "deckHref": "/decks/019de071-eb84-776b-8e7d-ce40a476afec",
  "deckJsonHref": "/decks/019de071-eb84-776b-8e7d-ce40a476afec.json",
  "deckAnchorHref": "/decks/019de071-eb84-776b-8e7d-ce40a476afec#slide-55",
  "components": [
    {
      "bbox": {
        "h": 0.75,
        "w": 0.65,
        "x": 0.32,
        "y": 0.15
      },
      "kind": "diagram",
      "text": "Flow diagram showing Phase 1a dose escalation (DL1 to DLx) and Phase 1b dose expansion cohorts for various patient populations and combination therapies.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d0f48cd7-3cd2-4368-bd92-3a0a2c99b050",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.28,
        "x": 0.03,
        "y": 0.17
      },
      "kind": "list",
      "text": "Key Eligibility Criteria: R/R B-cell lymphoma, >= 2 prior systemic regimens, Ineligible or refused CAR-T or ASCT. Primary Objective: To evaluate safety, PK/PD in MYD88 mutant and MYD88 wild-type R/R DLBCL. Study Endpoints: Primary, Secondary, Exploratory.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "76109459-3496-4a31-83a6-b39f97583aba",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.055,
        "w": 0.608,
        "x": 0.196,
        "y": 0.04
      },
      "kind": "title",
      "text": "KT-413: Clinical Study Design and Objectives",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f4def5dc-5e05-430f-ae44-f34214b4157c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "clinical-trial-design",
      "slug": null,
      "matchId": "1160c1e7-a5bc-4589-ad83-01af1a37cf19",
      "evidence": "The slide maps out the progression of a clinical trial from dose escalation to expansion cohorts.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}